21.08.19|Hezi SternlichtAn opioid-abuse lawsuit settlement reached by drugmakers Endo and Allergan Tuesday could bode well for Teva’s legal future, as does the release of an FDA-approved generic version of EpiPen JR
09.12.18|Lilach BaumerNovartis’ U.S. division Sandoz announced a planned release for early 2019. The company will sell its drug, which lacks the EpiPen’s auto-injector, for $250 a pair out of pocket, compared to Mylan and Teva’s $300
28.11.18|Lilach BaumerIn August, the Israel-headquartered drugmaker won approval to market the first generic EpiPen auto-injectors in the U.S.
26.08.18|Dror ReichThe Israeli drugmaker received approval for a first generic version of Mylan’s auto-injector earlier this month
More stories in CTech
